NIH:OVCAR-3 human ovarian cancer model

Ovarian cancer, a formidable gynecological malignancy, poses a significant threat to women's health worldwide.1 Its nature often leads to late-stage diagnosis, contributing to poor prognosis and limited treatment options. To unravel the complexities of this disease and pave the way for effective therapeutic strategies, extensivein vitro and in vivo research is crucial. The NIH:OVCAR-3 cell line stands out as a widely utilized and well-characterized model in this research.2 

Advancing ADC development: Overcoming preclinical challenges with Labcorp Discovery Oncology

Antibody-drug conjugates (ADCs) have transformed cancer treatment by merging the accuracy of targeted therapies with the strength of chemotherapy. These treatments utilize monoclonal antibodies to deliver potent chemotherapy drugs directly to cancer cells, sparing healthy cells from damage. This precise targeting has proven highly effective in treating various cancers, such as breast, lung, and hematologic malignancies, particularly in patients who have not responded to other treatments. As research progresses, ADCs are poised to become an increasingly crucial component of oncology. 

Getting the most out of limited samples

Comprehensive genomic profiling (CGP) is central to precision oncology, enabling biomarker discovery and trial optimization through next-generation sequencing (NGS). However, limited or degraded tumor tissue, especially from formalin-fixed paraffin-embedded (FFPE) samples, often compromises nucleic acid quality and sequencing outcomes.